PwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018

Size: px
Start display at page:

Download "PwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018"

Transcription

1 PwC Deals Global Pharma & Life Sciences Deals Insights Q 18 The increase in deal activity in Q 18 sets the stage for a strong second half of the year. Companies continue to review their portfolios for opportunities to create value through acquisitions or divestitures. Executive summary M&A values and volumes witnessed meaningful increases in Q 18, with volumes in the quarter reminiscent of 16 and 17 levels. Reversing course from the prior quarter, the Pharmaceutical subsector led in deal volume with a 0% increase in Q 18 over the prior quarter, returning volume to average historical levels. The rise in activity was in line with expectations due to pent up demand and surplus cash. Corporate divestitures continued to be active, as evidenced by announced and publicized deals including Sanofi/Zentiva, J&J/Advanced Sterilization, GE/GE Healthcare, and Eli Lilly/Elanco, as companies continue to reassess their strategic visions and shed assets that are not deemed to be part of their core operations. Private equity buyers, with significant levels of dry powder, are well positioned to acquire many of these carveouts, even with more robust pricing for these assets relative to recent historical periods. We expect Big Pharma to remain active and Biotech to see increased activity in Q3 18, as companies in these subsectors continue to build out their pipelines with smaller acquisitions of highquality assets. We expect the Medical Devices space to remain active, but likely in volumes rather than values. The Services/Other subsector experienced a soft quarter for activity, but given the continued consolidation in this area, we would expect an increase in future quarters. After a quarter filled with news around consolidation in the Pharma and Med Device subsectors, we anticipate more mega deals to drive deal activity in the second half of 18. These megadeals should continue to encourage greater competition for smaller targets as buyers hunt for scarce assets. Similar to prior quarters, we expect the recent trend of large divestitures to continue as companies reassess their offerings and look for ways to meet and exceed the level of growth investors expect. Glenn Hunzinger, US PLS Deals Leader, PwC Q 18 vs Q1 18 vs Q 17 Subsectors (see overleaf for commentary) Value by thenumbers $119.1B 1% 53% Recent Trends Outlook Increase in deal value vs Q1 18 Increase in deal value vs Q 17 Pharmaceutical Volume by the numbers 61 30% 9% Biotechnology Increase in deal volume vs Q1 18 Decrease in deal volume vs Q 17 Medical Devices Source: Capital IQ and PwC analysis Other/Services

2 Volume Value (USD in Billions) A deeper look into subsectors Subsector breakdown Q 18 Big Pharma experienced a significant increase in deal value in Q 18 driven mainly by Takeda s announced acquisition of Shire. Strategic fit and ability to create shareholder value given takeout premiums are the headwinds driving the current state of Big Pharma. Going forward, we believe the rest of 18 will be active for Big Pharma as stakeholders strive to build out robust pipelines of high potential assets. Additionally, divestitures will continue to be a major focus of Big Pharma as companies seek to extract value and reshape their portfolio. Biotech deal value and volume decreased 50% and 1%, respectively, in Q 18 as the prior quarter had a large acquisition by Sanofi and two by Celgene, surrendering its lead from the prior quarter back to the Pharma subsector. Going forward, we believe the value gaps will likely narrow, but more importantly that the larger Biotechs could be active in M&A as consolidation amongst the larger players is a possibility. Novel areas will likely drive demand as FDA approvals are at their highest level in years. The subsector will also experience some level of disruption given the focus on accelerating FDA approvals and the desire to start adopting advanced digital technologies in the R&D process. Medical Devices, including Diagnostics, increased 9% in deal value in Q 18 with Fortive s acquisition of J&J s Advanced Sterilization Products business for $.7B and Zoetis acquisition of Abaxis for $.0B. We believe the need for Medical Device companies to add scale and breadth to their product portfolios, while focusing on innovative, highgrowth therapeutic areas and shedding lowergrowth assets, still exists. As a result, the rest of 18 will likely be an active time for divestitures (with GE Healthcare as the most prominent) as well as acquisitions of smaller to medium sized bolton deals. We continue to expect the Medical Device subsector to pursue technology alliances and deals to maximize the value of product innovation. Specialty Pharma and Generics were slow this quarter as the Generics subsector continued to examine pricing declines and whether the market had bottomed out. Once this question is answered, we expect nonus (China, India, etc.) and Private Equity buyers to be active and to see "mergers of equals" as midmarket players look to create scale and ascend to category leadership. Strategic divestments will also continue to create stronger balance sheets and potentially brighter prospects. Import tariffs have the potential to impact US generic pharmaceutical companies that manufacture their drugs in the US, if they import active pharmaceutical ingredients from Asia. It is not yet clear what the impact might be on M&A for these generic manufacturers. Other/Services subsector (CRO, CMO, etc.) saw deal activity back down in Q 18 as deal flow in the subsector stalled out with only one significant transaction making up the bulk of the deal value (Altaris acquisition of Analogic). Overall, given the interest of Private Equity around the service businesses of PLS, we believe volumes will be active while values will decline given the larger consolidations and flurry of CRO activity in 17. We expect contract manufacturing for the Medical Device segment to continue a recent trend toward outsourcing. The need to scale, coupled with the alignment of holding periods and potential exits for private equity portfolio companies, are key considerations in contract manufacturing. Lastly, while Animal Health has not seen significant megadeal activity in the past several years (last larger deal being the BI/Sanofi Swap), we believe the rumored Lilly/Elanco divestiture may make Animal Health active. The previously mentioned Zoetis/Abaxis deal could start a trend toward increased activity in the diagnostics (including wearables), services and nondrug offerings within Animal Health. Also, cross pollination of the consumer/retail and companion animal space may bring new entrants to the industry as retailers look to vertically integrate. This type of activity was demonstrated with Mar s acquisition of veterinary firm AniCura. Subsector breakdown analysis historical activity Pharmaceutical Biotechnology Medical Devices Other/Services 9.3 Takeda announced $81.7B acquisition of Shire acquisitions each by Celgene and Sanofi totaling $33.3B Q3 17 Q4 17 Q1 18 Q 18 Q3 17 Q4 17 Q1 18 Q 18 Q3 17 Q4 17 Q1 18 Q 18 Q3 17 Q4 17 Q1 18 Q Q3 17 Q4 17 Q1 18 Q 18 Q3 17 Q4 17 Q1 18 Q 18 Q3 17 Q4 17 Q1 18 Q 18 Q3 17 Q4 17 Q1 18 Q 18 PwC Deals Global Pharma & Life Sciences Deals Insights Q 18

3 Deal Value ($ in billions) Number of deals Highlights of Q 18 deal activity Announced M&A transactions increased in Q 18 Deal volume increased in Q 18, breaking a streak of steady declines experienced since 16. The quarter also saw its second consecutive increase in deal value. This quarter included an announced $81.7B acquisition of Shire plc. by Takeda Pharmaceutical, resulting in a deal value that more than doubled the Q1 18 total. Novartis AG s acquisition of AveXis, Inc. for $8.7B also helped drive deal value higher in Q 18. While Q 18 included a megadeal that created a spike in deal value, the sector still experienced a notable increase in deal volume which may indicate a resurgence in the sector. Even after excluding the TakedaShire deal, deal value for Q 18 was above the levels experienced in Q3 and Q4 17. Pharma & life sciences deal volume and value Q3 16 Q4 16 Q1 17 Q 17 Q3 17 Q4 17 Q1 18 Q 18 Total Value Total Volume 1 Foreign deal activity takes lead In the prior quarter, almost half of the deal value came from US deals, compared to inbound, outbound and foreign transactions combined. However, in Q 18, foreign transactions took the lead for the second time in the past year. 1 1 US vs cross border deals by value Inbound deal value was mostly driven by the second largest transaction of the quarter, which was the $8.7 billion acquisition of AveXis, Inc. by Novartis AG. While inbound deals continue to represent a relatively small share of total value, we still expect tax reform to drive a renewed focus for foreign companies looking to expand operations in the US in the upcoming years. Additionally, tax reform could drive an increase in US deals as acquirers begin to develop acquisition strategies that take advantage of favorable legislative developments. Q3 17 Q4 17 Q1 18 Q 18 US Outbound Inbound Foreign Venture capital financing Venture capitalists invested $3.0 billion in 1,416 USbased deals in Q 18, according to the MoneyTree Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. Healthcare, as a whole, received the second largest amount of venture capital dollars, behind Internet, with $5.3 billion going into 16 deals. This activity represents a minimal change in dollars invested and a 1% increase in the number of deals, compared with Q1 18. According to the MoneyTree Report, Healthcare deal share was greater than Mobile & Telecom activity (historically the second largest slice of deal share) for the second consecutive quarter in Q 18. The quarter was fueled by 45 megarounds of $ million or more for US companies, 10 more than Q1 18. According to Tom Ciccolella, US Venture Capital Leader at PwC, Deal activity looks to be resurgent with $3B invested in VCbacked startups setting a new quarterly funding record, while also increasing activity to over 1,0 deals. San Francisco and New York were the largest players in VC funding, with 464 deals in total, representing 33% of all deals for the quarter. Source: PwC MoneyTree Report Q 18 PwC Deals Global Pharma & Life Sciences Deals Insights Q 18 3

4 Key trends and insights Top PLS deals of Q 18 Announced Target Name Target nation Acquirer name Acquirer nation Deal value Segment 04/19/18 Shire plc Channel Islands Takeda Japan 81,667 Pharma Pharmaceutical 04/09/18 AveXis, Inc. United States Novartis AG Switzerland 8,696 Biotech 06/18/18 China Biologic Products Holdings, Inc. Cayman Islands CITIC Capital Holdings Limited Hong Kong 3,3 Biotech 06/06/18 Advanced Sterilization Products Services, Inc. 04/16/18 Oncology Business of Shire United States Fortive Corporation United States,700 Medical Devices Ireland Les Laboratoires Servier SAS 05/14/18 MedReleaf Corp. Canada Aurora Cannabis Inc. 06/8/18 Zentiva Group, a.s. Czech Republic Advent International Corporation France,0 Pharma Canada,391 Pharma United States, Pharma 05/16/18 Abaxis, Inc. United States Zoetis Inc. United States 1,995 Medical Devices 05/10/18 ARMO BioSciences, Inc. United States Eli Lilly and Company United States 1,68 Biotech 05/04/18 Sirtex Medical Limited Australia CDH Investments China 1,49 Biotech Deals by target geography Western Europe was the dominant deal value target region for the first time in the last 4 quarters, driven by the TakedaShire megadeal. North America was the deal volume leader with 39% of total deal volume. After the TakedaShire megadeal, the next nine largest transactions for the quarter saw a relatively even split of deal value between US, inbound, and foreign deals. Targets in the Asia Pacific region saw a slight increase from Q1 18 to Q 18, going from 1% of total deal value to 3% of deal value. However, deal volume for targets in the region increased from 4 deals in Q1 18 to 1 deals in Q 18. United States $.5 billion; 17% Western Europe $85.5 billion; 7% Rest of the World $10.1 billion; 8% AsiaPacific $3.0 billion; 3% The rest of the world saw a small increase from Q1 18 to Q 18, going from 6% of total deal value to 8% of deal value. PwC Deals Global Pharma & Life Sciences Deals Insights Q 18 4

5 About PwC s Deals Practice Glenn Hunzinger Partner, US Pharmaceutical and Life Sciences Leader PwC s Deals Practice glenn.hunzinger@pwc.com Brian Geiger Principal, PwC s Deals Practice brian.geiger@pwc.com For a deeper discussion on pharmaceutical and life sciences deal considerations, please contact our practice leader: Bob Saada US Deals Leader, PwC s Deals Practice bob.d.saada@pwc.com PwC s Deals professionals help clients understand the risks in transactions so they can be confident that they are making informed strategic decisions. From deal negotiations to capturing synergies during integration, we help clients gain value and ultimately deliver this value to stakeholders. For companies in distressed situations, we advise on crisis avoidance, financial and operational restructuring, and bankruptcy. PwC s Deals Practice can advise pharmaceutical and life sciences companies and PLSfocused private equity firms on a range of M&A decisions, from identifying acquisition or divestiture candidates and performing detailed buyside diligence, through developing strategies for capturing postdeal profits, to exiting a deal through a sale, carveout, or IPO. Our seasoned deals teams combine deep pharmaceutical and life sciences industry skills with local market knowledge. With more than,000 deals practitioners worldwide, we can deploy seasoned teams that combine deep health services industry skills with local market knowledge virtually anywhere your company operates or executes transactions. Although each deal is unique, most will benefit from the broad experience we bring to delivering strategic M&A advice, due diligence, transaction structuring, M&A tax, merger integration, valuation, and postdeal services. In short, we offer integrated solutions tailored to your particular deal situation and designed to help you complete and extract peak value within your risk profile, whether your focus is deploying capital through an acquisition or joint venture, raising capital through an IPO or private placement, or harvesting an investment through the divestiture process. For more information about M&A and related services in the pharmaceutical and life sciences industry, please visit or For our views on the health industries sector, refer to the Global Pharma & Life Sciences Deals Insights reports on the deals section of our website. About the data We define M&A activity as mergers and acquisitions in which targets are USbased companies acquired by US or foreign buyers, or foreign targets acquired by US or foreign pharmaceutical and life sciences companies. We define divestitures as the sale of a portion of a company (not a whole entity) by a USbased or foreign seller. We have based our findings on data provided by industryrecognized sources. Specifically, values and volumes used throughout this report are based on announcement date for transactions with a disclosed deal value greater than $15 million, as provided by Capital IQ, as of June 30, 18, and supplemented by additional independent research. Information related to previous periods is updated periodically based on new data collected by Capital IQ for deals closed during previous periods but not reflected in previous data sets. Deal information was sourced from Capital IQ and includes deals for which buyers or targets fall into one of the PLS industry subsectors: biotechnology, medical devices, pharmaceuticals, or other (such as contract manufacturing organizations). Certain adjustments have been made to the information to exclude transactions that are not specific to the PLS industry. Capital market and equity return information is sourced from Capital IQ. 18 PwC. All rights reserved. PwC refers to the US member firm or one of its subsidiaries or affiliates, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see for further details. Disclaimer: This content is for general information purposes only, and should not be used as a substitute for consultation with professional advisors.

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease

More information

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for

More information

VENTURE CAPITAL INVESTING REACHES HIGHEST LEVEL SINCE Q WITH $13.0 BILLION INVESTED DURING Q2 2014, ACCORDING TO THE MONEYTREE REPORT

VENTURE CAPITAL INVESTING REACHES HIGHEST LEVEL SINCE Q WITH $13.0 BILLION INVESTED DURING Q2 2014, ACCORDING TO THE MONEYTREE REPORT Contacts: Clare Chachere, PwC US, 512-867-8737, clare.chachere@us.pwc.com Jeffrey Davidson, Brainerd Communicators for PwC, 212-739-6733, davidson@braincomm.com Ben Veghte, NVCA, 703-778-9292, bveghte@nvca.org

More information

Moving Ahead. Third-quarter Technology venture capital investment increased 33 percent yearover-year. percent quarter-over-quarter.

Moving Ahead. Third-quarter Technology venture capital investment increased 33 percent yearover-year. percent quarter-over-quarter. Moving Ahead Third-quarter Technology venture capital investment increased 33 percent yearover-year but decreased 6 percent quarter-over-quarter October 2 PwC US venture capital funding for the Technology

More information

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd. IVC-MEITAR HIGH-TECH EXITS H1/ 215 REPORT IVC-Meitar 214 Exits Report Prepared by IVC Research Center Ltd. Israeli High-Tech Exit Highlights Exit proceeds in H1/215 reached ¾ of total exits for 214 Average

More information

Silicon Valley Venture Capital Survey Second Quarter 2018

Silicon Valley Venture Capital Survey Second Quarter 2018 fenwick & west Silicon Valley Venture Capital Survey Second Quarter 2018 Full Analysis Silicon Valley Venture Capital Survey Second Quarter 2018 fenwick & west Full Analysis Cynthia Clarfield Hess, Mark

More information

2013 venture capital trends summary

2013 venture capital trends summary 213 venture capital trends summary Prepared by: Hitesh Kothari, Director, McGladrey LLP hitesh.kothari@mcgladrey.com August 213 Fundraising by venture capital funds In the first half of 213, 88 venture

More information

VENTURE-BACKED IPO EXIT ACTIVITY KEEPS MOMENTUM WITH BEST FULL YEAR FOR NEW LISTINGS SINCE 2007; THIRD CONSECUTIVE QUARTER FOR 20+ OFFERINGS SINCE

VENTURE-BACKED IPO EXIT ACTIVITY KEEPS MOMENTUM WITH BEST FULL YEAR FOR NEW LISTINGS SINCE 2007; THIRD CONSECUTIVE QUARTER FOR 20+ OFFERINGS SINCE CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY KEEPS

More information

Private Equity Market Update. February 2013

Private Equity Market Update. February 2013 Private Equity Market Update February 213 U.S. Private Equity Deal Activity Deal activity in the first three quarters of 212 was lower than the corresponding quarters in 211 due to a number of factors.

More information

Asia Pacific UK Cross border transactions. Corporate Finance PRECISE. PROVEN. PERFORMANCE.

Asia Pacific UK Cross border transactions. Corporate Finance PRECISE. PROVEN. PERFORMANCE. Asia Pacific UK Cross border transactions PRECISE. PROVEN. PERFORMANCE. Cross border transactions Our services Moore Stephens global network of offices allows us to combine expert knowledge and advice

More information

Venture-Backed Exit Activity Shows Improved Signs of Life in Q1 2010

Venture-Backed Exit Activity Shows Improved Signs of Life in Q1 2010 CONTACTS Channa Brooks Tenor Communications for NVCA 1.302.368.2345 channa@tenorcom.com Daniel Billings Thomson Reuters 1.646 223 5985 daniel.billings@thomsonreuters.com Exit Activity Shows Improved Signs

More information

Israel Venture Capital Investments Report Q3 2017

Israel Venture Capital Investments Report Q3 2017 Israel Venture Capital Investments Report Q3 2017 NOVEMBER 2017 Summary of Israeli Venture Capital Raising Q3/2017 +14% from Q2/2017 Israeli high-tech capital raising summed up to $1.44B @ ALL RIGHTS RESERVED.

More information

The percentage of Series A rounds declined significantly, to 12% of all deals.

The percentage of Series A rounds declined significantly, to 12% of all deals. Silicon Valley Venture Capital Survey Fourth Quarter 2012 Barry Kramer and Michael Patrick Fenwick fenwick & west llp Background We analyzed the terms of venture financings for 116 companies headquartered

More information

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Fenwick fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Survey Introduction

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 3Q 2015 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000 CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN

More information

Trends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp

Trends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Fenwick fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Survey Intro and Background

More information

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back. Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City

More information

2013 Global venture capital confidence survey results. How confident are investors?

2013 Global venture capital confidence survey results. How confident are investors? 2013 Global venture capital confidence survey results How confident are investors? August 14, 2013 Contents Survey methodology, demographics and key findings Economic trends Regional and country investing

More information

CANADIAN PRIVATE EQUITY BUYOUT REVIEW

CANADIAN PRIVATE EQUITY BUYOUT REVIEW CANADIAN PRIVATE EQUITY BUYOUT REVIEW First Half 2016 REUTERS Table of Contents Canada s PE Buyout Market in Q2 2016 3 $ Invested and # Companies Financed 5 Top Buyout Deals 9 Canada by Market Segment

More information

Mergers and Acquisitions/ Private Equity. Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors. Attorney Advertising

Mergers and Acquisitions/ Private Equity. Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors. Attorney Advertising Mergers and Acquisitions/ Private Equity Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors Attorney Advertising In every transaction, business perspective informs our legal strategy.

More information

2014 Global venture capital confidence survey results

2014 Global venture capital confidence survey results 2014 Global venture capital confidence survey results How confident are investors? August 13, 2014 Contents Survey methodology, demographics and key findings Economic trends Regional and country investing

More information

Florida Venture Factbook

Florida Venture Factbook S E AT T L E SAN FRANCISCO NEW YORK LONDON Florida Venture Factbook 2019 pitchbook.com US + 1 206.623.1986 UK + 44 (0)207.190.9809 demo@pitchbook.com PG 1 Dear Attendee, On behalf of the Florida Venture

More information

Cannabis Practice Group

Cannabis Practice Group Cannabis Practice Group McMillan LLP Vancouver Calgary Toronto Ottawa Montréal Hong Kong Cannabis mcmillan.ca Practice Group 1 Medical cannabis is booming and McMillan is at the forefront of developments

More information

EVCA Strategic Priorities

EVCA Strategic Priorities EVCA Strategic Priorities EVCA Strategic Priorities The following document identifies the strategic priorities for the European Private Equity and Venture Capital Association (EVCA) over the next three

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

As our brand migration will be gradual, you will see traces of our past through documentation, videos, and digital platforms.

As our brand migration will be gradual, you will see traces of our past through documentation, videos, and digital platforms. We are now Refinitiv, formerly the Financial and Risk business of Thomson Reuters. We ve set a bold course for the future both ours and yours and are introducing our new brand to the world. As our brand

More information

BDO & PITCHBOOK: SHATTERING OF INDUSTRY, GLOBAL SILOS DRIVES HEALTHCARE DEAL ACTIVITY

BDO & PITCHBOOK: SHATTERING OF INDUSTRY, GLOBAL SILOS DRIVES HEALTHCARE DEAL ACTIVITY BDO & PITCHBOOK: SHATTERING OF INDUSTRY, GLOBAL SILOS DRIVES HEALTHCARE DEAL ACTIVITY CONTENTS SECTION Frothy Political Waters Could Dampen Cross-Border Opportunity with China 3 SECTION China as the New

More information

VentureSource Europe -- 3Q 2014

VentureSource Europe -- 3Q 2014 Europe -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, and liquidity. The included charts and graphs offer a

More information

January Bob DeSutter Managing Director Co-Head of Health Care

January Bob DeSutter Managing Director Co-Head of Health Care January 2007 Dear Friends and Clients, For much of our 112 year history, serving innovative health care companies has been an important part of our mission at Piper Jaffray. Our goal is to be lead advisor

More information

2Q13. Trends in Terms of Venture Financings in Silicon Valley. Second Quarter fenwick & west llp

2Q13. Trends in Terms of Venture Financings in Silicon Valley. Second Quarter fenwick & west llp 2Q13 Trends in Terms of Venture Financings in Silicon Valley Second Quarter 2013 Fenwi wick fenwick & west llp Silicon Valley Venture Capital Survey Second Quarter 2013 Barry Kramer and Michael Patrick

More information

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,

More information

Life Sciences Outlook. New York City 2016

Life Sciences Outlook. New York City 2016 Life Sciences Outlook City 2016 City is emerging as a leading destination for biotech startups and the larger life sciences industry. Investors have committed millions of dollars throughout the city and

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

PwC s Academy. Mastering. Mergers & Acquisitions

PwC s Academy. Mastering. Mergers & Acquisitions PwC s Academy Mastering Mergers & Acquisitions Developing and managing a successful portfolio of businesses requires taking the right path to acquire, redeploy or divest resources and capabilities. Whether

More information

Mara H. Rogers, Partner Norton Rose Fulbright

Mara H. Rogers, Partner Norton Rose Fulbright Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers

More information

Silicon Valley Venture Capital Survey Third Quarter 2017

Silicon Valley Venture Capital Survey Third Quarter 2017 fenwick & west Silicon Valley Venture Capital Survey Third Quarter 2017 Full Analysis Silicon Valley Venture Capital Survey Third Quarter 2017 fenwick & west Full Analysis Cynthia Clarfield Hess, Mark

More information

PANEL DISCUSSION & ROUNDTABLES

PANEL DISCUSSION & ROUNDTABLES LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the

More information

Average M&A Deal Size at Highest Level Since 2004

Average M&A Deal Size at Highest Level Since 2004 CONTACTS Ben Veghte NVCA 1.703.778.9292 bveghte@nvca.org Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MAINTAINS MOMENTUM WITH BEST QUARTER

More information

Venture financings in 3Q12 continued to show solid price increases from their prior round, but 3Q12 was not as strong as 2Q12.

Venture financings in 3Q12 continued to show solid price increases from their prior round, but 3Q12 was not as strong as 2Q12. Silicon Valley Venture Capital Survey Third Quarter 2012 Barry Kramer and Michael Patrick Fenwick fenwick & west llp Background We analyzed the terms of venture financings for 117 companies headquartered

More information

Trends in Healthcare Investments and Exits 2018

Trends in Healthcare Investments and Exits 2018 Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview

More information

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on

More information

Purvi B. Maniar Member of the Firm

Purvi B. Maniar Member of the Firm Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the

More information

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &

More information

Fortis to acquire strategic stake in Parkway Holdings, Singapore

Fortis to acquire strategic stake in Parkway Holdings, Singapore PRESS RELEASE Fortis to acquire strategic stake in Parkway Holdings, Singapore Landmark cross border deal in Healthcare sector out of India Move will establish Fortis as Asia s largest hospital network

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Private Equity and Venture Capital in Switzerland

Private Equity and Venture Capital in Switzerland Private Equity and Venture Capital in Switzerland Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Overview

More information

International Presence, Local Expertise. Introductory Presentation

International Presence, Local Expertise. Introductory Presentation International Presence, Local Expertise Introductory Presentation About GlobalM&A Partners Established in 1999 A partnership of 38 leading independent M&A firms Over 200 active dealmakers supported by

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management M&A Update 1H 2017 Accounts Receivable Management Healthcare IT Revenue Cycle Management Proven. Focused. Trusted. 301-576-4000 www.greenberg-advisors.com Proven. Focused. Trusted Revenue Cycle Management

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

Venture Capital Research Report Q4 2017

Venture Capital Research Report Q4 2017 Venture Capital Research Report Q4 2017 As of February 9, 2018 Executive Summary VC market in the US Regional share of investment VC market in the SF Bay Area Annual VC investment in the SF Bay Area VC

More information

2017 Venture Capital Update. Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017

2017 Venture Capital Update. Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017 2017 Venture Capital Update Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017 Agenda U.S. VC trends through year-end 2016 VC trends in Texas & Dallas Policy priorities

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 1Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost

More information

Q Q Cleantech Investment Monitor VOL. 7 / ISSUE 1.

Q Q Cleantech Investment Monitor VOL. 7 / ISSUE 1. Q1 2008 Q1 2008 VOL. 7 / ISSUE 1 Cleantech Investment Monitor we put the squeaky in your CLEAN If you are a cleantech leader looking to engage advocates worldwide with strategic PR, please contact: William

More information

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Energy. Practice. Group

Energy. Practice. Group Energy Practice Group The Energy Practice Group is a multi-disciplinary group of investment banking advisors within Corporate Finance Associates. Collectively, the Energy Practice Group provides M&A advice

More information

The Future of Growth and the Energy Industry

The Future of Growth and the Energy Industry The Future of Growth and the Energy Industry July 20, 2017 Grant Thornton LLP. All rights reserved. 1 Our Speakers Steve Toon Editor in Chief Oil and Gas Investor Kevin Schroeder National Managing Partner,

More information

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2011)

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2011) Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2011) Background We analyzed the terms of venture financings for 117 companies headquartered in Silicon Valley that reported raising

More information

Information Technology: McGladrey Quarterly Private Equity Deal Flow Profile

Information Technology: McGladrey Quarterly Private Equity Deal Flow Profile Information Technology: McGladrey Quarterly Private Equity Deal Flow Profile Q3 2011 Insight Analysis Experience the power of being understood. SM Powered by PitchBook McGladrey Announces the Q3 2011 Private

More information

Unique. Perspective. Corporate Finance Advice and Investment Banking. Our unique perspective is client-focused rather than transaction-focused.

Unique. Perspective. Corporate Finance Advice and Investment Banking. Our unique perspective is client-focused rather than transaction-focused. Unique SM Perspective Our unique perspective is client-focused rather than transaction-focused. Corporate Finance Advice and Investment Banking Welcome to MidMarket Capital Advisors. It is our pleasure

More information

Venture Capital Industry Overview. Powered By:

Venture Capital Industry Overview. Powered By: Venture Capital Industry Overview Powered By: U.S. U.S. Fundraising Fundraising Slows in 1Q 05 Commitments to Venture Capital Funds $80 $83.5 Funds Raised ($B) $60 $40 $20 $0 $58.8 $50.5 $26.9 $17.1 $17.7

More information

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010)

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010) Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010) Background We analyzed the terms of venture financings for 126 companies headquartered in Silicon Valley that reported raising

More information

Private Equity-Backed Buyout Deals and Exits Down in Q Market Volatility and Tightened Credit Markets Lead to an Absence of Large-Cap Deals

Private Equity-Backed Buyout Deals and Exits Down in Q Market Volatility and Tightened Credit Markets Lead to an Absence of Large-Cap Deals Press Release 3 rd October 211 Equity-Backed Buyout Deals and Exits Down in 211 Market Volatility and Tightened Credit Markets Lead to an Absence of Large-Cap Deals Preqin s quarterly deals data shows

More information

Life Sciences Tools, Diagnostics, & Services Q Industry Overview

Life Sciences Tools, Diagnostics, & Services Q Industry Overview Life Sciences Tools, Diagnostics, & Services Q4 2017 Industry Overview Life Sciences Tools, Diagnostics, & Services: Industry Overview Key Takeaways M&A activity has remained steady at high volumes of

More information

Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiatin

Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiatin Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiating, e.g., joint venture, purchase and participation

More information

Press Release 1 st April 2014

Press Release 1 st April 2014 Press Release 1 st April 214 Private Equity-Backed Buyout Investment Across North America Up 5% in Q1 214 Compared to Q4 213 North American private equity-backed buyout investment totalled $48bn during

More information

CANADIAN PRIVATE EQUITY BUYOUT REVIEW

CANADIAN PRIVATE EQUITY BUYOUT REVIEW CANADIAN PRIVATE EQUITY BUYOUT REVIEW First Three Quarters 2015 REUTERS / Todd Korol Table of Contents Canada s PE Buyout Market in First 3Q 2015 3 $ Invested and # Companies Financed 5 Top Buyout Deals

More information

Recent marquee transactions

Recent marquee transactions Recent marquee transactions EY the leading advisor in the Indian M&A market April 2014 EY refers to the global organization, and/or one or more of the independent member firms of Ernst & Young Global Limited

More information

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW Global Transcatheter Aortic Valve Replacement (TAVR) Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region, By Country: Opportunities and Forecast (2017-2022) By Type of Approach-

More information

Guidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation

Guidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation Guidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation Ministry of Industry and Information Technology National Development and Reform Commission Ministry of Finance

More information

Be inspired. Your future with Orrick in Asia

Be inspired. Your future with Orrick in Asia Be inspired Your future with Orrick in Asia Why Join Orrick? Let us give you a few reasons We are a strong and expanding international firm Orrick has more than 1,100 lawyers in 25 offices worldwide. Over

More information

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017 KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform December 2017 Strategic BDC Partnership Introduction On December 11, 2017, KKR and FS Investments

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

Financing Sources, Sales Pitch to Investors BARCELONA Aitana Peire Venture Valuation

Financing Sources, Sales Pitch to Investors BARCELONA Aitana Peire Venture Valuation 30.04.2014 Aitana Peire Venture Valuation Venture Valuation Mission Independent assessment and valuation of technology driven companies / products in growth industries Information services / Life Sciences

More information

GLOBAL PRIVATE EQUITY Report Charts

GLOBAL PRIVATE EQUITY Report Charts GLOBAL PRIVATE EQUITY 2003 Report Charts THE WORLD VIEW Investment & Fund Raising Trends THE WORLD VIEW 2002 Main Headlines At least $102 billion of private equity and venture capital was invested globally

More information

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS INDUSTRY RE FUNDS 1969 to present Industry surveys, quarterly and annual fund reports 9,240+ venture capital and private equity funds Venture capital and buyout funds that have invested in companies Name

More information

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 11, 2016 Gross Returns $1B+ Carry Paying Funds Q4 and 2015 Performance Market Indices Private Equity Real Assets Alternative

More information

European Trends in Healthcare Investments and Exits 2018

European Trends in Healthcare Investments and Exits 2018 European Trends in Healthcare Investments and Exits 2018 ANNUAL REPORT 2018 Nooman Haque Managing Director Life Science & Healthcare Bobby Anderson Senior Associate Life Science & Healthcare Vojtech Trebicky

More information

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number

More information

CeQur establishes Wales subsidiary

CeQur establishes Wales subsidiary FOR IMMEDIATE RELEASE CeQur establishes Wales subsidiary -- Arthurian Life Sciences investment helps bring to market world s first three-day simple insulin infusion device for type 2 diabetes -- LUCERNE,

More information

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant

More information

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is

More information

HOLDING REDLICH UPDATE - M & A

HOLDING REDLICH UPDATE - M & A 2018 M&A Review With many market commentators anticipating 2018 as a strong year for M&A, Holding Redlich s experience in the first half of 2018 has been consistent with this. The deals in which our team

More information

Chartwell Introduction and AEC Capabilities

Chartwell Introduction and AEC Capabilities Chartwell Introduction and AEC Capabilities Comprehensive Financial Advisory Experience Chartwell provides financial advisory solutions to the middle market; areas of expertise include corporate finance,

More information

François G. Laugier's Representative Experience

François G. Laugier's Representative Experience François G. Laugier's Representative Experience Practice Area: International, Mergers & Acquisitions Key Issues: Acquisitions (For Buyer) Client Type: Foreign Publicly-Traded Naval Technology Company Description:

More information

VENUE Market Spotlight PE BUYOUTS. February 2017 Edition

VENUE Market Spotlight PE BUYOUTS. February 2017 Edition VENUE Market Spotlight PE BUYOUTS February 2017 Edition WELCOME CONTENTS Foreword 3 Survey 4 Private Equity deals 10 in the room About Donnelley 11 Financial Solutions Dear Valued Reader, Welcome to the

More information

ROBOTICS M&A REPORT 2017 AN UPDATE ON THE STATE OF THE MARKET

ROBOTICS M&A REPORT 2017 AN UPDATE ON THE STATE OF THE MARKET ROBOTICS M&A REPORT 2017 AN UPDATE ON THE STATE OF THE MARKET Dr. Jürg Stucker Oaklins Robotics Specialist j.stucker@ch.oaklins.com David Zürrer Oaklins Robotics Specialist d.zuerrer@ch.oaklins.com INTRODUCTION

More information

Oil & Gas Update M&A Market Trends and Bankruptcy Outcomes

Oil & Gas Update M&A Market Trends and Bankruptcy Outcomes Oil & Gas Update M&A Market Trends and Bankruptcy Outcomes William Snyder, Advisory Principal, Corporate Restructuring Services, Deloitte & Touche LLP John Little, Advisory Principal, Corporate Restructuring

More information

Enayat Qasimi. Partner. Experience M Street, NW Suite 450N Washington, DC Phone: Fax:

Enayat Qasimi. Partner. Experience M Street, NW Suite 450N Washington, DC Phone: Fax: 2018 Whiteford, Taylor & Preston LLP Enayat Qasimi Partner 1800 M Street, NW Suite 450N Washington, DC 20036 Phone: 202.659.6792 Fax: 202.327.6174 Email: eqasimi@wtplaw.com Experience Mr. Qasimi?s practice

More information

Venture Capital Report

Venture Capital Report China 4Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs offer

More information

Trends in private equity healthcare investments

Trends in private equity healthcare investments Trends in private equity healthcare investments How private equity investors are adapting to changes in healthcare DOMINIC COTTONE Managing Director, Ferguson Partners AMANDA PIGOTT Vice President, Ferguson

More information

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn

More information

AFTER NEARLY 3 YEARS OF STEADY GROWTH, U.S. VENTURE INVESTMENT PULLS BACK 7% IN 1 ST QUARTER TO $6.84 BILLION

AFTER NEARLY 3 YEARS OF STEADY GROWTH, U.S. VENTURE INVESTMENT PULLS BACK 7% IN 1 ST QUARTER TO $6.84 BILLION FOR IMMEDIATE RELEASE For more information: Adam Wade Dow Jones Financial Information Services (415) 439-6666 adam.wade@dowjones.com AFTER NEARLY 3 YEARS OF STEADY GROWTH, U.S. VENTURE INVESTMENT PULLS

More information

Software was the Most Active and Highest Value Segment in 3Q17 with 606 Transactions Totaling $29.4 Billion in Reported Deal Value

Software was the Most Active and Highest Value Segment in 3Q17 with 606 Transactions Totaling $29.4 Billion in Reported Deal Value jd1 3Q17 Summary of M&A and Investment Activity in the : 814 Totaling a $49.4 Billion Software was the Most Active and Highest Value Segment in 3Q17 with 606 Totaling $29.4 Billion in Deal Value During

More information